Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of MediWound's EscharEx?
EscharEx is an enzyme commercialized by MediWound, with a leading Phase II program in Diabetic Foot Ulcers;Venous Leg Ulcers (Crural...
Data Insights
EscharEx by MediWound for Diabetic Foot Ulcers: Likelihood of Approval
EscharEx is under clinical development by MediWound and currently in Phase II for Diabetic Foot Ulcers. According to GlobalData, Phase...